Background: Definitive concurrent chemoradiation (CCRT) has become a standard therapeutic alternative for patients (pts) with esophageal squamous cell carcinoma (ESCC). Studies with this strategy using platin/fluoropyrimidine-based chemotherapy have shown median survival of 17 to 19 months, and 5 years survival comparable with surgery, allowing organ preservation. Methods: We performed a retrospective study of pts with ESCC treated with definitive CCRT between 2002 and 2012. Our chemotherapy schedules were: cisplatin 20 mg/m2 day 1 to 3 plus bolus 5FU 300 mg/m2 day 1 to 3 plus leucovorin 20 mg/m2 day 1 to 3 every 2 weeks for 3 cycles, or paclitaxel 50 mg/m2 plus carboplatin AUC 2 day 1, 8, 15, 22, 29 and 35, both schedules given concurrently with RT (median dose: 60 Gy). Results: 223 consecutive patients were included in the analysis with a median follow up of 20.4 months. Median age 63 years, 54% male, 72% and 30% with history of smoking and alcohol respectively. Stage at diagnosis: II (60, 1%), III (35, 4%) and IV (4, 5%). Most of the pts had performance status 1. Histology was moderately differentiated in 63%. Primary tumor was localized more frequently in medium (52%) and inferior (32%) esophagus. More than 85% of the pts had severe dysphagia at diagnosis. In 75% of pts a feeding tube was inserted before treatment. Treatment was temporary interrupted in 50, 2% of pts (due to social reasons, problems with the RT equipment and toxicity). Four patients died during treatment. Grade III-IV toxicity was uncommon (mucositis 9%, neutropenia 8.6%, asthenia 6.3%). At the end of CCRT, complete relief of dysphagia was achieved in 47.5%, partial relief in 24% and only 8.3% of pts suffered progression of dysphagia. 52% of patients were interpreted as clinical complete responders (clinical, endoscopic and radiological evaluation). In 14 of 16 pts treated with carboplatin and paclitaxel based CCRT a clinical complete response was achieved. Median survival was 26 months (m). In the multivariate analysis, clinical complete response (43 vs 16m, p = 0.0001), relief of dysphagia (25 vs 9m, p = 0.0003) and no interruption of CCRT (26 vs 12m, p = 0.0003) had statistical impact in survival. Conclusion: In our population of pts with ESCC, definitive concurrent chemoradioterapy without surgery had a safety profile and efficacy comparable to other international series. We consider this approach as a standard option in our clinical practice. Efforts must be done to avoid interruptions of treatment to improve the rate of clinical complete response.
Read full abstract